Key result
Nesiritide significantly improved left ventricular ejection fraction, cardiac index, and urine volumes, and decreased PCWP and BNP levels without increasing mortality risk compared to control drugs.
Why the study?
The study was conducted to evaluate the efficacy and safety of nesiritide in patients with acute myocardial infarction and heart failure.
Does nesiritide improve cardiac function and safety outcomes in patients with acute myocardial infarction and heart failure?
Meta-Analysis (n=870)
Does nesiritide improve cardiac function and safety outcomes in patients with acute myocardial infarction and heart failure?
Nesiritide improves hemodynamic and biomarker profiles without increasing adverse events in patients with AMI and heart failure.
Answers are grounded in this paper and cite their sources.
Supports nesiritide consideration in AMI with HF; extends meta-analytic evidence on its role.
Objective This meta-analysis evaluated the efficacy and safety of nesiritide in patients with acute myocardial infarction (AMI) and heart failure. Methods PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception through December 2018. Studies including patients with AMI and heart failure who received nesiritide were identified. Results Ten trials involving 870 participants were included in this meta-analysis. Nesiritide treatment significantly increased left ventricular ejection fraction, cardiac index, and 24- and 72-hour urine volumes. Additionally, pulmonary capillary wedge pressure, right atrial pressure, and brain natriuretic peptide and N-terminal brain natriuretic peptide levels were significantly decreased in patients treated with nesiritide compared with those treated with control drugs. However, patients treated with nesiritide did not have an increased risk of mortality compared with those treated with control drugs. There were no differences between the two groups with respect to heart rate or the risk of readmission, hypotension, or renal dysfunction. Conclusions Nesiritide appears to be safe for patients with AMI and heart failure, and it improves global cardiac and systemic function.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2020) conducted a meta-analysis in Acute myocardial infarction and heart failure (n=870). Nesiritide vs. Control drugs was evaluated on Efficacy and safety (including LVEF, cardiac index, urine volumes, PCWP, RAP, BNP, and mortality). Nesiritide significantly improved left ventricular ejection fraction, cardiac index, and urine volumes, and decreased PCWP and BNP levels without increasing mortality risk compared to control drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: